Atropine eyedrops

ISOPTO ATROPINE

Open Atropine eyedrops in the interactive console ↗

What it isAtropine sulfate 1% eyedrops (ISOPTO ATROPINE, 1960), a topical antimuscarinic for mydriasis, cycloplegia, and amblyopia penalization.

Why this oneIts prolonged cycloplegia enables patch-free amblyopia penalization, pediatric refraction, and relief of ciliary spasm.

What limits itOcular dosing yields ~64% systemic bioavailability (plasma t1/2 ~2.5 h); the label restricts use under 3 months and flags Down syndrome susceptibility.

FDA-approved for

mydriasis / cycloplegia (1960)
amblyopia (penalization of the healthy eye) (1960)

FDA label

Read the full label on DailyMed ↗

FDA dosing	Population	Start	Target	Max
Mydriasis; cycloplegia; penalization of healthy eye in amblyopia	≥3 months	1 drop to conjunctival cul-de-sac, 40 min before intended maximal dilation time	Same	See age limits
Same indications — repeat dosing	≥3 years	May repeat up to BID PRN	—	BID
Same indications — age cap	<3 years	≤1 drop per eye QD	—	1 drop/eye/day; <3 months not recommended

Renal Undefined

Hepatic Undefined

Not recommended <3 months of age; <3 years limit to ≤1 drop per eye per day

Instructions

Instill topically into the cul-de-sac of the conjunctiva
Administer 40 min before intended maximal dilation time

Cautions

Photophobia and blurred vision (pupil unresponsiveness/cycloplegia) may last up to 2 weeks
Blood pressure elevation from systemic absorption reported at recommended doses
Down syndrome, spastic paralysis, or brain damage: increased susceptibility to CNS, cardiopulmonary, and GI toxicity from systemic absorption

Adverse reactions

Ocular: eye pain/stinging on instillation, blurred vision, photophobia, superficial keratitis, decreased lacrimation; less common allergic (papillary conjunctivitis, contact dermatitis, eyelid edema)
Systemic (antimuscarinic): dry skin/mouth/throat, drowsiness, restlessness/irritability/delirium, tachycardia, increased BP, flushed face/neck

Pregnancy No adequate human studies; systemically bioavailable after ocular dosing — use only if potential benefit justifies fetal risk

Lactation Unknown presence in milk/effects on infant or production; weigh benefits vs maternal need

NO BOXED WARNINGS